RGC vs. STE: A Head-to-Head Stock Comparison

Updated on October 18, 2025

Here’s a clear look at RGC and STE, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.

Company Profile

Symbol	RGC	STE
Company Name	Regencell Bioscience Holdings Limited	STERIS plc
Country	Hong Kong	United States
GICS Sector	Health Care	Health Care
GICS Industry	Pharmaceuticals	Health Care Equipment & Supplies
Market Capitalization	9.59 billion USD	23.87 billion USD
Exchange	NasdaqCM	NYSE
Listing Date	July 16, 2021	June 1, 1992
Security Type	Common Stock	Common Stock

Historical Performance

This chart compares the performance of RGC and STE by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.

RGC vs. STE: Growth of a $10,000 investment over the past one year.

Historical Performance at a Glance

Symbol	RGC	STE
5-Day Price Return	26.66%	-0.03%
13-Week Price Return	3.83%	4.78%
26-Week Price Return	3,133.87%	9.45%
52-Week Price Return	18,127.27%	7.22%
Month-to-Date Return	29.77%	-2.07%
Year-to-Date Return	15,323.08%	17.89%
10-Day Avg. Volume	0.24M	0.62M
3-Month Avg. Volume	1.00M	0.58M
3-Month Volatility	90.19%	22.59%
Beta	2.26	1.04

Profitability

Return on Equity (TTM)

RGC

-54.75%

Pharmaceuticals Industry

Max: 38.59%
Q3: 19.84%
Median: 11.85%
Q1: 5.40%
Min: -10.91%

RGC has a negative Return on Equity of -54.75%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.

STE

9.47%

Health Care Equipment & Supplies Industry

Max: 29.93%
Q3: 16.99%
Median: 9.28%
Q1: 5.10%
Min: -12.52%

STE’s Return on Equity of 9.47% is on par with the norm for the Health Care Equipment & Supplies industry, indicating its profitability relative to shareholder equity is typical for the sector.

RGC vs. STE: A comparison of their Return on Equity (TTM) against their respective Pharmaceuticals and Health Care Equipment & Supplies industry benchmarks.

Net Profit Margin (TTM)

RGC

Pharmaceuticals Industry

Max: 40.67%
Q3: 19.07%
Median: 12.31%
Q1: 4.50%
Min: -9.91%

Net Profit Margin data for RGC is currently unavailable.

STE

11.26%

Health Care Equipment & Supplies Industry

Max: 24.41%
Q3: 13.71%
Median: 10.08%
Q1: 5.96%
Min: -5.58%

STE’s Net Profit Margin of 11.26% is aligned with the median group of its peers in the Health Care Equipment & Supplies industry. This indicates its ability to convert revenue into profit is typical for the sector.

RGC vs. STE: A comparison of their Net Profit Margin (TTM) against their respective Pharmaceuticals and Health Care Equipment & Supplies industry benchmarks.

Operating Profit Margin (TTM)

RGC

Pharmaceuticals Industry

Max: 45.78%
Q3: 23.14%
Median: 16.68%
Q1: 7.98%
Min: -7.13%

Operating Profit Margin data for RGC is currently unavailable.

STE

30.13%

Health Care Equipment & Supplies Industry

Max: 31.09%
Q3: 18.11%
Median: 15.07%
Q1: 8.48%
Min: -0.28%

An Operating Profit Margin of 30.13% places STE in the upper quartile for the Health Care Equipment & Supplies industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.

RGC vs. STE: A comparison of their Operating Profit Margin (TTM) against their respective Pharmaceuticals and Health Care Equipment & Supplies industry benchmarks.

Profitability at a Glance

Symbol	RGC	STE
Return on Equity (TTM)	-54.75%	9.47%
Return on Assets (TTM)	-51.38%	6.07%
Net Profit Margin (TTM)	--	11.26%
Operating Profit Margin (TTM)	--	30.13%
Gross Profit Margin (TTM)	--	44.01%

Financial Strength

Current Ratio (MRQ)

RGC

42.68

Pharmaceuticals Industry

Max: 4.65
Q3: 2.64
Median: 1.85
Q1: 1.26
Min: 0.78

RGC’s Current Ratio of 42.68 is exceptionally high, placing it well outside the typical range for the Pharmaceuticals industry. This indicates a very strong liquidity position, though such a high ratio may also suggest that the company is not using its assets efficiently to generate profits.

STE

2.22

Health Care Equipment & Supplies Industry

Max: 5.19
Q3: 3.00
Median: 2.13
Q1: 1.44
Min: 0.86

STE’s Current Ratio of 2.22 aligns with the median group of the Health Care Equipment & Supplies industry, indicating that its short-term liquidity is in line with its sector peers.

RGC vs. STE: A comparison of their Current Ratio (MRQ) against their respective Pharmaceuticals and Health Care Equipment & Supplies industry benchmarks.

Debt-to-Equity Ratio (MRQ)

RGC

0.00

Pharmaceuticals Industry

Max: 1.75
Q3: 0.82
Median: 0.35
Q1: 0.13
Min: 0.00

Falling into the lower quartile for the Pharmaceuticals industry, RGC’s Debt-to-Equity Ratio of 0.00 points to a conservative financing strategy. This results in lower financial risk but potentially limits strategic investments compared to more leveraged competitors.

STE

0.27

Health Care Equipment & Supplies Industry

Max: 1.61
Q3: 0.76
Median: 0.45
Q1: 0.14
Min: 0.00

STE’s Debt-to-Equity Ratio of 0.27 is typical for the Health Care Equipment & Supplies industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.

RGC vs. STE: A comparison of their Debt-to-Equity Ratio (MRQ) against their respective Pharmaceuticals and Health Care Equipment & Supplies industry benchmarks.

Interest Coverage Ratio (TTM)

RGC

Pharmaceuticals Industry

Max: 103.95
Q3: 43.60
Median: 9.83
Q1: 2.37
Min: -42.71

Interest Coverage Ratio data for RGC is currently unavailable.

STE

11.23

Health Care Equipment & Supplies Industry

Max: 56.35
Q3: 25.56
Median: 9.60
Q1: 3.78
Min: -26.49

STE’s Interest Coverage Ratio of 11.23 is positioned comfortably within the norm for the Health Care Equipment & Supplies industry, indicating a standard and healthy capacity to cover its interest payments.

RGC vs. STE: A comparison of their Interest Coverage Ratio (TTM) against their respective Pharmaceuticals and Health Care Equipment & Supplies industry benchmarks.

Financial Strength at a Glance

Symbol	RGC	STE
Current Ratio (MRQ)	42.68	2.22
Quick Ratio (MRQ)	41.89	1.32
Debt-to-Equity Ratio (MRQ)	0.00	0.27
Interest Coverage Ratio (TTM)	--	11.23

Growth

Revenue Growth

RGC vs. STE: A side-by-side comparison of their Revenue Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

EPS Growth

RGC vs. STE: A side-by-side comparison of their EPS Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

Dividend

Dividend Yield (TTM)

RGC

0.00%

Pharmaceuticals Industry

Max: 7.14%
Q3: 3.45%
Median: 2.17%
Q1: 0.33%
Min: 0.00%

RGC currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.

STE

0.94%

Health Care Equipment & Supplies Industry

Max: 4.15%
Q3: 1.76%
Median: 0.79%
Q1: 0.00%
Min: 0.00%

STE’s Dividend Yield of 0.94% is consistent with its peers in the Health Care Equipment & Supplies industry, providing a dividend return that is standard for its sector.

RGC vs. STE: A comparison of their Dividend Yield (TTM) against their respective Pharmaceuticals and Health Care Equipment & Supplies industry benchmarks.

Dividend Payout Ratio (TTM)

RGC

0.00%

Pharmaceuticals Industry

Max: 199.58%
Q3: 97.17%
Median: 53.47%
Q1: 22.97%
Min: 0.00%

RGC has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.

STE

35.77%

Health Care Equipment & Supplies Industry

Max: 160.00%
Q3: 66.60%
Median: 27.49%
Q1: 0.00%
Min: 0.00%

STE’s Dividend Payout Ratio of 35.77% is within the typical range for the Health Care Equipment & Supplies industry, suggesting a balanced approach between shareholder payouts and company reinvestment.

RGC vs. STE: A comparison of their Dividend Payout Ratio (TTM) against their respective Pharmaceuticals and Health Care Equipment & Supplies industry benchmarks.

Dividend at a Glance

Symbol	RGC	STE
Dividend Yield (TTM)	0.00%	0.94%
Dividend Payout Ratio (TTM)	0.00%	35.77%

Valuation

Price-to-Earnings Ratio (TTM)

RGC

Pharmaceuticals Industry

Max: 45.19
Q3: 27.91
Median: 20.59
Q1: 15.08
Min: 3.79

P/E Ratio data for RGC is currently unavailable.

STE

38.69

Health Care Equipment & Supplies Industry

Max: 67.29
Q3: 47.01
Median: 30.94
Q1: 23.91
Min: 10.79

STE’s P/E Ratio of 38.69 is within the middle range for the Health Care Equipment & Supplies industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.

RGC vs. STE: A comparison of their Price-to-Earnings Ratio (TTM) against their respective Pharmaceuticals and Health Care Equipment & Supplies industry benchmarks.

Price-to-Sales Ratio (TTM)

RGC

Pharmaceuticals Industry

Max: 8.87
Q3: 4.56
Median: 2.14
Q1: 1.58
Min: 0.11

P/S Ratio data for RGC is currently unavailable.

STE

4.27

Health Care Equipment & Supplies Industry

Max: 9.49
Q3: 5.41
Median: 2.86
Q1: 2.07
Min: 0.74

STE’s P/S Ratio of 4.27 aligns with the market consensus for the Health Care Equipment & Supplies industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.

RGC vs. STE: A comparison of their Price-to-Sales Ratio (TTM) against their respective Pharmaceuticals and Health Care Equipment & Supplies industry benchmarks.

Price-to-Book Ratio (MRQ)

RGC

9.57

Pharmaceuticals Industry

Max: 9.78
Q3: 4.99
Median: 2.48
Q1: 1.53
Min: 0.59

RGC’s P/B Ratio of 9.57 is in the upper tier for the Pharmaceuticals industry. This indicates that investors are paying a premium relative to the company’s net assets, a valuation that hinges on its ability to generate superior profits.

STE

3.37

Health Care Equipment & Supplies Industry

Max: 10.85
Q3: 6.56
Median: 3.53
Q1: 2.36
Min: 0.71

STE’s P/B Ratio of 3.37 is within the conventional range for the Health Care Equipment & Supplies industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.

RGC vs. STE: A comparison of their Price-to-Book Ratio (MRQ) against their respective Pharmaceuticals and Health Care Equipment & Supplies industry benchmarks.

Valuation at a Glance

Symbol	RGC	STE
Price-to-Earnings Ratio (TTM)	--	38.69
Price-to-Sales Ratio (TTM)	--	4.27
Price-to-Book Ratio (MRQ)	9.57	3.37
Price-to-Free Cash Flow Ratio (TTM)	--	26.17